Gamco Investors INC. ET AL increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 7.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,545 shares of the life sciences company’s stock after acquiring an additional 606 shares during the period. Gamco Investors INC. ET AL’s holdings in Illumina were worth $3,146,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the stock. Next Capital Management LLC purchased a new stake in Illumina during the second quarter valued at about $25,000. Strategy Asset Managers LLC purchased a new stake in shares of Illumina during the first quarter worth about $26,000. C J Advisory Inc purchased a new stake in shares of Illumina during the first quarter worth about $29,000. Mizuho Securities Co. Ltd. bought a new position in Illumina in the first quarter worth about $37,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in Illumina in the second quarter worth about $37,000. Institutional investors own 90.92% of the company’s stock.
Shares of ILMN stock opened at $300.91 on Friday. The stock has a market capitalization of $40.58 billion, a P/E ratio of 52.61, a P/E/G ratio of 2.57 and a beta of 1.09. Illumina, Inc. has a 12-month low of $263.30 and a 12-month high of $380.76. The firm’s 50 day moving average is $287.45 and its 200 day moving average is $313.82. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The firm had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The company’s revenue was up 1.0% on a year-over-year basis. During the same period last year, the firm earned $1.43 EPS. As a group, equities analysts predict that Illumina, Inc. will post 6.04 earnings per share for the current year.
A number of equities analysts have weighed in on ILMN shares. Argus decreased their target price on shares of Illumina to $340.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Wolfe Research assumed coverage on shares of Illumina in a research report on Thursday, May 30th. They set an “outperform” rating for the company. Cowen reduced their price target on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a research report on Friday, July 12th. Piper Jaffray Companies reduced their price target on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a research report on Tuesday, July 30th. Finally, Deutsche Bank reduced their price target on shares of Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a research report on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $330.92.
In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction on Monday, June 17th. The shares were sold at an average price of $349.28, for a total value of $3,492,800.00. Following the sale, the senior vice president now directly owns 65,994 shares in the company, valued at approximately $23,050,384.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Charles Dadswell sold 124 shares of Illumina stock in a transaction on Monday, July 1st. The shares were sold at an average price of $371.29, for a total transaction of $46,039.96. The disclosure for this sale can be found here. Insiders have sold a total of 56,198 shares of company stock worth $17,773,470 over the last 90 days. Insiders own 0.38% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.